Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
- 1Merck & Co., Inc., Rahway, NJ 07065, USA
- 2Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Abstract
Background: Durvalumab is currently approved as consolidation therapy for patients with unresectable stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent chemoradiotherapy (cCRT). This study described real-world characteristics, disease progression, subsequent treatment, and clinical outcomes according to durvalumab receipt. Methods: This retrospective cohort study used the N-Power Medicine database. Adults diagnosed with unresectable stage III NSCLC who initiated cCRT between February 2018 and October 2023 and subsequently received durvalumab or no durvalumab and were followed until October 2025. Baseline characteristics, disease progression, and subsequent treatment patterns were summarized descriptively. Kaplan–Meier methods were used to estimate overall survival (OS) and time to death or distant metastasis (TDDM). Results: Among 717 patients who initiated cCRT, 487 received cCRT followed by durvalumab and 230 received cCRT only. Baseline characteristics were broadly similar between cohorts. Median theoretical follow-up was 60.5 and 60.8 months, respectively. Disease progression was observed in both groups, with higher rates in the cCRT-only cohort (48.7% vs. 40.9%). TDDM was 26.7 months in the cCRT + durvalumab cohort and 5.6 months in the cCRT-only cohort. Median OS was 42.6 months and 11.4 months, and OS events occurred in 55.2% and 80.0% of patients, respectively. In the cCRT + durvalumab cohort, OS rates at 12, 36 and 60 months were 83.6%, 56.0%, and 42.8%. Conclusions: In real-world practice, approximately one-third of patients with unresectable stage III NSCLC did not receive durvalumab following cCRT. Despite consolidation therapy, a substantial proportion of patients continue to experience disease progression, highlighting ongoing unmet need in this population.
Related
- Prognostic impact of immune-related adverse events in non-completers of durvalumab consolidation therapy for non-small cell lung cancer: a single-center retrospective cohort study
- A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment
- Immune-mediated Myocarditis after Durvalumab/tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
- Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
- Cadonilimab plus gemcitabine and cisplatin as first-line treatment for unresectable locally advanced or metastatic biliary tract malignancies: the phase II bicureX clinical trial
BibTeX
@article{rai2026realworld,
title = {{Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study}},
author = {Pragya Rai and Yu-Han Kao and Xiaohan Hu and Ashwini Arunachalam and Andrew Song and Stephen V. Liu},
journal = {Journal of Clinical Medicine},
year = {2026},
month = nov,
doi = {10.3390/jcm15218561},
url = {https://www.mdpi.com/2077-0383/15/21/8561},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Real-World Clinical Outcomes and Treatment Patterns in Patients with Unresectable Stage III NSCLC Treated with CCRT With or Without Durvalumab as Consolidation Therapy: A Retrospective Cohort Study
AU - Pragya Rai
AU - Yu-Han Kao
AU - Xiaohan Hu
AU - Ashwini Arunachalam
AU - Andrew Song
AU - Stephen V. Liu
PY - 2026
DA - 2026/11/03
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218561
UR - https://www.mdpi.com/2077-0383/15/21/8561
AB - Background: Durvalumab is currently approved as consolidation therapy for patients with unresectable stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent chemoradiotherapy (cCRT). This study described real-world characteristics, disease progression, subsequent treatment, and clinical outcomes according to durvalumab receipt. Methods: This retrospective cohort study used the N-Power Medicine database. Adults diagnosed with unresectable stage III NSCLC who initiated cCRT between February 2018 and October 2023 and subsequently received durvalumab or no durvalumab and were followed until October 2025. Baseline characteristics, disease progression, and subsequent treatment patterns were summarized descriptively. Kaplan–Meier methods were used to estimate overall survival (OS) and time to death or distant metastasis (TDDM). Results: Among 717 patients who initiated cCRT, 487 received cCRT followed by durvalumab and 230 received cCRT only. Baseline characteristics were broadly similar between cohorts. Median theoretical follow-up was 60.5 and 60.8 months, respectively. Disease progression was observed in both groups, with higher rates in the cCRT-only cohort (48.7% vs. 40.9%). TDDM was 26.7 months in the cCRT + durvalumab cohort and 5.6 months in the cCRT-only cohort. Median OS was 42.6 months and 11.4 months, and OS events occurred in 55.2% and 80.0% of patients, respectively. In the cCRT + durvalumab cohort, OS rates at 12, 36 and 60 months were 83.6%, 56.0%, and 42.8%. Conclusions: In real-world practice, approximately one-third of patients with unresectable stage III NSCLC did not receive durvalumab following cCRT. Despite consolidation therapy, a substantial proportion of patients continue to experience disease progression, highlighting ongoing unmet need in this population.
SN - 2077-0383
ER -